A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer
Authors:
- 1 May 2015
- journal article
- Published by SAGE Publications in Thyroid®
- Vol. 25 (5) , 563-564
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinomaEuropean Journal of Endocrinology, 2006
- Retinoid X receptor-γ and peroxisome proliferator-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatmentMolecular Cancer Therapeutics, 2004
- Retinoic Acid and Retinoid X Receptors Are Differentially Expressed in Thyroid Cancer and Thyroid Carcinoma Cell Lines and Predict Response to Treatment with RetinoidsThe Journal of Clinical Endocrinology & Metabolism, 2004
- Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.2001